Vensana Capital I GP, LLC sold SGP

February 9, 2026 · Form 4 insider transaction

Vensana Capital I GP, LLC sold 9,689,922 shares of SpyGlass Pharma, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 1 day after the transaction.

Direction
Disposed (sell-side)
Shares
9,689,922
Price
N/A
Total value
N/A
Role10% owner
SecuritySeries B Preferred Stock
Transaction codeC: Conversion of a derivative
Transaction dateFebruary 9, 2026
Filing dateFebruary 10, 2026
Shares owned after0
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.; These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

View the original Form 4 on SEC EDGAR